Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores.

Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores. Abstract Text:

John M Keith,Ann J Barbier,Sandy J Wilson,Kirstin Miller,Jamin D Boggs,Ian C Fraser,Curt Mazur,Timothy W Lovenberg,Nicholas I Carruthers,

A series of tetrahydroisoquinolines acting as dual serotonin transporter inhibitor/histamine H(3) antagonists is described. The introduction of polar aromatic spacers as part of the histamine H(3) pharmacophore was explored. A convergent synthesis of the final products allowing late stage introduction of the aromatic side chain was developed. In vitro and in vivo data are discussed.

Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores. Publishing Authors By Initials

JM Keith,AJ Barbier,SJ Wilson,K Miller,JD Boggs,IC Fraser,C Mazur,TW Lovenberg,NI Carruthers,

For similar heterocyclic compounds: heterocyclic compounds, 2-ring: isoquinolines: tetrahydroisoquinolines research abstracts see: heterocyclic compounds: heterocyclic compounds, 2-ring: isoquinolines: tetrahydroisoquinolines research

PUBMED ID PMID:

MEDLINE DATE:

Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Bioorganic & medicinal chemistry letters

VOLUME: 17

Page Numbers: 5325-9

Journal Abbreviation: Bioorg. Med. Chem. Lett.

ISSN: 0960-894X

DAY: 15

MONTH: 08

YEAR: 2007

Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9107377

Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores. Keywords Mesh Terms:

KEYWORDS: Tetrahydroisoquinolines

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores. Information

Substance Name: 5-Hydroxytryptophan

Registry Number: 56-69-9

Grant and Affiliation Information for Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores.

AFFILIATION: Johnson & Johnson Pharmaceutical Research and Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA. jkeith@prdus.jnj.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bioorg Med Chem Lett

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores Related Publications

• 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.
• A cleavable propeptide influences Toxoplasma infection by facilitating the trafficking and secretion of the TgMIC2-M2AP invasion complex.
• A transient forward-targeting element for microneme-regulated secretion in Toxoplasma gondii.
• ATP-dependent sugar transport complexity in human erythrocytes.
• Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
• Broadening discussions of "safe" in hepatitis C prevention: A close-up of swabbing in an analysis of video recordings of injecting practice.
• Caveat emptor (buyer beware).
• Discussion: the history of injectable silicone fluids for soft-tissue augmentation.
• Dual serotonin transporter inhibitor/histamine H3 antagonists: development of rigidified H3 pharmacophores.
• Elderly patients with hypertension should retain 'special' status.
• Endocrine and superovulatory responses in heifers pretreated with FSH or bovine follicular fluid.
• Host cell manipulation by the human pathogen Toxoplasma gondii.
• Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid.
• Laboratory testing of spermicidal preparation.
• Lead identification of acetylcholinesterase inhibitors-histamine H(3) receptor antagonists from molecular modeling.
• MARveling at parasite invasion.
• Mad cows, prions, and wrinkles.
• Malakoplakia: report of a case.
• Patient-reported outcomes with botulinum neurotoxin type A.
• Recent medicinal chemistry of the histamine H3 receptor.
• Reminders in echocardiography reports increased use of blockers in reduced left ventricular ejection fraction.
• Shrinking upper and lower eyelid skin with a novel radiofrequency tip.
• Some points in the diagnosis of labyrinthine vertigo and a survey of methods of treatment, medical and surgical.
• Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.
• The J-curve--it is clinically relevant?
• The diagnosis of late life hypogonadism.
• The evolution of botulinum neurotoxin type A for cosmetic applications.
• The organization of a community: community-based prevention of injecting drug use-related health problems.
• The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action.
• [Not Available.]